David S. Hong, MD, discusses the data supporting the use of larotrectinib for the treatment of TRK fusion-positive lung tumors. He also explains the difference between larotrectinib another FDA-approved TRK inhibitor, entrectinib.
David S. Hong, MD, deputy chair, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the data supporting the use of larotrectinib (Vitrakvi) for the treatment of TRK fusion-positive lung tumors. He also explains the difference between larotrectinib another FDA-approved TRK inhibitor, entrectinib (Rozlytrek).
0:08 | So, I think larotrectinib has the most robust data at this point, number of patients, etc than entrectinib. And it was different in the sense it's less of a nonspecific inhibitor. It also targets ROS, and those who are developing and entrectinib and involved with entrectinib will tell you that it may be an advantage. But it's interesting that the majority of patients who have NTRK fusions rarely have any other alterations, they just have NTRK fusions.
0:40 | So, my bias given the fact that I also helped develop this drug is that patients who have NTRK fusions should be getting an NTRK inhibitor of some sort. In my opinion, larotrectinib given the robustness of the data, the number of patients etc. Overall, the overall response rates are a little bit better with larotrectinib. Right now, it's not clear whether progression-free survival or overall survival are any better, but that's why I would consider larotrectinib.
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More